AstraZeneca PLC CEO Pascal Soriot had repeatedly assured investors the company could reach its $80 billion revenue target by the start of the next decade without relying on a major acquisition. Privately, however, he was orchestrating a megadeal. According to multiple sources, Soriot had struggled in recent years to secure a transformative merger; his initial overtures to executives at several top U.S. pharmaceutical firms were all rebuffed. It was Bristol-Myers Squibb CEO Chris Boerner who became Soriot's willing partner for a potential transatlantic blockbuster transaction.
The two companies held negotiations from spring through summer. By early August, sources say, they were deep in talks about a primarily stock-based acquisition: AstraZeneca PLC planned to buy Bristol-Myers Squibb at a premium. At the end of July, AstraZeneca PLC had a market value of 196 billion pounds (approximately $264 billion), while Bristol-Myers Squibb was valued at $133 billion—a gap that underscores the sheer scale of the proposed deal. The parties were close to finalizing the purchase price and were contacting several major U.S. banks to arrange financing for the cash portion of the deal, which was expected to be tens of billions of dollars. By 2028, nearly half of Bristol-Myers Squibb's revenue was at risk from patent expirations.
According to insiders, negotiations had reached an advanced stage, with AstraZeneca PLC and Bristol-Myers Squibb originally planning to announce the acquisition publicly in mid-August. Legal and financial advisory teams were working overtime to meet the deadline. However, on August 2, news broke that the two companies were in talks for a $400 billion merger, which would create the world's largest pharmaceutical company by revenue. That revelation shattered the 67-year-old Soriot's vision of finalizing the deal. By the time London markets opened on Monday, August 3, AstraZeneca PLC's board was already preparing to halt the negotiations.
The merger news sent shockwaves through the pharmaceutical industry and the U.K. AstraZeneca PLC, the second-largest constituent of the FTSE 100, is considered a crown jewel of British industry. Multiple sources say that Whitehall officials were deeply unsettled, forming a cross-departmental task force led by the Prime Minister's chief business advisor, Varun Chandra, with members from Downing Street and the Cabinet Office. Government officials worried that AstraZeneca PLC might use the merger to move its operational headquarters to the U.S., following a trend of other major British companies.
On August 3, AstraZeneca PLC's shares fell sharply, closing down 9%—its worst single-day performance since the COVID-19 pandemic hit global markets in March 2020. Many investors were baffled by the company's pursuit of such a massive deal and voiced collective opposition to the potential transaction. That evening, the board, led by Chairman Michel Demaré, formally ordered the termination of merger talks. Neither company issued an official statement about the negotiations. AstraZeneca PLC and Bristol-Myers Squibb both declined to comment for this article.
Had the merger gone through, it would have marked a return to the early 2000s era of massive pharmaceutical consolidation, which produced many industry giants, including AstraZeneca PLC, GlaxoSmithKline, Merck, and Pfizer. The last major wave of pharma integration ended in the late 2010s, highlighted by Bristol-Myers Squibb's $74 billion acquisition of biotech Celgene. That deal faced strong investor resistance and ultimately failed to deliver the returns many had hoped for. Costa Kleeman, a healthcare investor at Thread needle Asset Management, which holds shares in both AstraZeneca PLC and Bristol-Myers Squibb, stated, "The concept of this merger is outdated. AstraZeneca PLC has strong growth momentum and could easily acquire promising early-stage biotech firms. Why take on the looming patent cliff of Bristol-Myers Squibb?"
The negotiations also raised concerns among investors, who began to question AstraZeneca PLC's confidence in its own drug pipeline. AstraZeneca PLC has a robust pipeline, with several high-profile oncology drug clinical data readouts expected in the next 12 months. Bristol-Myers Squibb faces its own patent cliff: by 2028, nearly half of its revenue could be lost to patent expirations, which would add further pressure to AstraZeneca PLC after the acquisition. As Soriot approaches his 15th year at the helm, investors are also questioning his strategic direction. Lucas Leoy, a portfolio manager at ATG Medical in Zurich, who holds AstraZeneca PLC shares, commented, "In my view, this deal would have been a misstep. Soriot has already built a strong legacy with impressive results over the past few years. There's no need to pursue such a massive transaction."
Beyond political concerns in the U.K., the deal faced other hurdles. Investors feared that a merger of this scale would inevitably face intense antitrust scrutiny, as both companies have large, well-regarded oncology businesses.